Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Documents de recerca, 1 registres trobats
Articles 3 registres trobats  
1.
5 p, 5.1 MB Life-threatening and life-saving inappropriate implantable cardioverter defibrillator shocks / Pérez Rodon, Jordi (Universitat Autònoma de Barcelona) ; Doiny, David (Universitat Autònoma de Barcelona) ; Miranda, Berta (Universitat Autònoma de Barcelona) ; Rivas Gándara, Nuria (Universitat Autònoma de Barcelona) ; Roca Luque, Ivo (Universitat Autònoma de Barcelona) ; Francisco Pascual, Jaume (Universitat Autònoma de Barcelona) ; Lidón, Rosa Maria (Universitat Autònoma de Barcelona) ; García Dorado, David (Universitat Autònoma de Barcelona) ; Moya Mitjans, Angel (Universitat Autònoma de Barcelona)
An implantable cardioverter defibrillator (ICD) lead dislodgement into the right atrium is a dangerous situation, particularly in patients in atrial fibrillation because atrial fibrillation can be sensed as ventricular fibrillation and true ventricular fibrillation induced with an inappropriate shock. [...]
2017 - 10.1002/ccr3.893
Clinical Case Reports, Vol. 5, Issue 4 (April 2017) , p. 521-525  
2.
10 p, 426.6 KB A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies / Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Delord, J. P. (Institut Claudius Regaud (France)) ; Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ; Berge, Y. (Institut Claudius Regaud (France)) ; Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ; Cottura, E. (Institut Claudius Regaud (France)) ; Bedard, P. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Akimov, M. (Novartis Pharma AG (Switzerland)) ; Lu, H. (Novartis Pharmaceuticals Corp (USA)) ; Pain, S. (Novartis Pharmaceuticals Corp (USA)) ; Kaag, A. (Novartis Pharma AG (Switzerland)) ; Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Cortés Castán, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659  
3.
21 p, 3.3 MB Single Intracoronary Injection of Encapsulated Antagomir-92a Promotes Angiogenesis and Prevents Adverse Infarct Remodeling / Bellera, Neus (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Barba, Ignasi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Rodriguez-Sinovas, Antonio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ferret, Eulalia (I+D Pierre-Fabre Ibérica S.A) ; Asín, Miguel Angel (I+D Pierre-Fabre Ibérica S.A) ; Gonzalez-Alujas, MªTeresa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Pérez-Rodon, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Esteves, Marielle (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Fonseca, Carla (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Toran, Nuria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia del Blanco, Bruno (Department of Cardiology, Hospital Vall d′Hebron, Universitat Autònoma de Barcelona) ; Pérez, Amadeo (I+D Pierre-Fabre Ibérica S.A) ; Garcia-Dorado, David (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Small and large preclinical animal models have shown that antagomir-92a-based therapy reduces early postischemic loss of function, but its effect on postinfarction remodeling is not known. In addition, the reported remote miR-92a inhibition in noncardiac organs prevents the translation of nonvectorized miR-targeted therapy to the clinical setting. [...]
2014 - 10.1161/JAHA.114.000946
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol. 3 (september 2014)  

Documents de recerca 1 registres trobats  
1.
201 p, 1.8 MB Optimización del tratamiento farmacológico en pacientes con disfunción sistólica severa del ventrículo izquierdo en una unidad de insuficiencia cardiaca: implicaciones en la indicación de un desfibrilador automático implantable en prevención primaria y factores predictores de ausencia de remodelado reverso del ventrículo izquierdo / Pérez Rodon, Jordi ; Galve Basilio, Enrique, dir. ; Moya Mitjans, Àngel, dir. ; García Dorado, D., dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
[Barcelona] : Universitat Autònoma de Barcelona, 2016  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.